KP-413 / Kaken Pharma, Bausch Health  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
KP-413 / Bausch Health, Kaken Pharma
NCT00932074: A Study to Determine the Safety, Tolerability and Efficacy of KP-413 in Subjects With Atopic Dermatitis(AD)

Completed
1/2
58
US
KP-413 Ointment
Kaken Pharmaceutical, Dow Pharmaceutical Sciences
Atopic Dermatitis
06/10
06/10

Download Options